Wealth Architects LLC Trims Stock Holdings in Cencora, Inc. (NYSE:COR)

Wealth Architects LLC lessened its stake in shares of Cencora, Inc. (NYSE:COR) by 7.1% in the third quarter, HoldingsChannel reports. The firm owned 1,377 shares of the company’s stock after selling 106 shares during the quarter. Wealth Architects LLC’s holdings in Cencora were worth $310,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD acquired a new position in shares of Cencora in the first quarter valued at approximately $2,183,619,000. JPMorgan Chase & Co. purchased a new stake in Cencora in the 1st quarter worth approximately $1,199,695,000. Boston Partners purchased a new stake in Cencora in the 1st quarter worth approximately $1,001,269,000. Capital Research Global Investors acquired a new position in Cencora in the 1st quarter valued at $650,424,000. Finally, Bessemer Group Inc. purchased a new position in shares of Cencora during the 1st quarter worth $556,245,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Wells Fargo & Company upped their target price on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. Leerink Partners cut their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. JPMorgan Chase & Co. raised their target price on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Bank of America reaffirmed a “neutral” rating and set a $245.00 price target (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Finally, Robert W. Baird decreased their price target on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a report on Friday, September 6th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $259.44.

Cencora Stock Performance

Shares of COR stock opened at $245.38 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The company has a market cap of $48.35 billion, a PE ratio of 26.64, a P/E/G ratio of 1.49 and a beta of 0.44. The company’s fifty day simple moving average is $231.57 and its 200-day simple moving average is $230.64. Cencora, Inc. has a 52 week low of $191.11 and a 52 week high of $247.66.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 15.80% of the stock is currently owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.